Monchusi, Bernice ADube, PhumzileTakundwa, Mutsa MKenmogne, Vanelle LThimiri Govinda Raja, Deepak B2024-11-212024-11-212024-081877-11731878-0814DOI: 10.1016/bs.pmbts.2024.07.004http://hdl.handle.net/10204/13833CRISPR-Cas systems have revolutionised precision medicine by enabling personalised treatments tailored to an individual's genetic profile. Various CRISPR technologies have been developed to target specific disease-causing genes in blood cancers, and some have advanced to clinical trials. Although some studies have explored the in vivo applications of CRISPR-Cas systems, several challenges continue to impede their widespread use. Furthermore, CRISPR-Cas technology has shown promise in improving the response of immunotherapies to blood cancers. The emergence of CAR-T cell therapy has shown considerable success in the targeting and correcting of disease-causing genes in blood cancers. Despite the promising potential of CRISPR-Cas in the treatment of blood cancers, issues related to safety, ethics, and regulatory approval remain significant hurdles. This comprehensive review highlights the transformative potential of CRISPR-Cas technology to revolutionise blood cancer therapy.AbstractenBlood cancersCRISPR-CasClinical trialsEx vivoGenome editingIn vivoPrecision medicineArticleN/A